Corneal Nerve Loss in Patients With TIA and Acute Ischemic Stroke in Relation To Circulating Markers of Inflammation and Vascular Integrity

Adnan Khan

Weill Cornell Medicine-Qatar

Aijaz Parray

Hamad Medical Corporation

Naveed Akhtar

Hamad Medical Corporation

Abdelali Agouni

Qatar University

Saadat Kamran

Hamad Medical Corporation

Sajitha V. Pananchikkal

Hamad Medical Corporation

Ruth Priyanka

Hamad Medical Corporation

Hoda Gad

Weill Cornell Medicine-Qatar

Georgios Ponirakis

Weill Cornell Medicine-Qatar

Ioannis N. Petropoulos

Weill Cornell Medicine-Qatar

Kuan-Han Chen

Weill Cornell Medicine-Qatar

Kausar Tayyab

Weill Cornell Medicine-Qatar

Maher Saqqur

University of Toronto Mississauga

Ashfaq Shuaib

University of Alberta

Rayaz A. Malik (✉ ram2045@qatar-med.cornell.edu)

Weill Cornell Medicine-Qatar

Research Article

Keywords: Biomarkers, Corneal nerves, Corneal confocal microscopy, IL-6

Posted Date: October 29th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-301595/v2>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Scientific Reports on February 28th, 2022. See the published version at <https://doi.org/10.1038/s41598-022-07353-7>.

Abstract

Background

Vascular and inflammatory mechanisms are implicated in the development of cerebrovascular disease and corneal nerve loss occurs in patients with transient ischemic attack (TIA) and acute ischemic stroke (AIS). We have assessed whether serum markers of inflammation and vascular integrity are associated with the severity of corneal nerve loss in patients with TIA and AIS.

Methods

Corneal confocal microscopy (CCM) was performed to quantify corneal nerve fiber density (CNFD), corneal nerve branch density (CNBD), corneal nerve fiber length (CNFL) in 105 patients with TIA or AIS and age matched control subjects (n=56). Circulating levels of IL-6, MMP-2, MMP-9, E-Selectin, P-Selectin and VEGF were quantified in patients within 48 hours of presentation with a TIA or AIS.

Results

CNFL (P=0.000, P=0.000), CNFD (P=0.122, P=0.000) and CNBD (P=0.002, P=0.000) were reduced in patients with TIA and AIS compared to controls, respectively with no difference between patients with AIS and TIA. The NIHSS Score (P=0.000), IL-6 (P=0.011) and E-Selectin (P=0.032) were higher in patients with AIS compared to TIA with no difference in MMP-2 (P=0.636), MMP-9 (P=0.098), P-Selectin (P=0.395) and VEGF (P=0.831). CNFL (r=0.218, P=0.026) and CNFD (r=0.230, P=0.019) correlated with IL-6 and multiple regression analysis showed a positive association of CNFL and CNFD with IL-6 (P=0.041, P=0.043).

Conclusions

Patients with TIA and stroke have evidence of corneal nerve loss and elevated IL6 and E-selectin levels. Larger longitudinal studies are required to determine the association between inflammatory and vascular markers and corneal nerve fiber loss in patients with cerebrovascular disease.

Background

Cerebrovascular disease is the leading cause of acquired disability and the second leading cause of death in the world¹. In Qatar, patients with acute stroke are younger than other parts of the world and do not necessarily have the traditional risk factors for stroke^{2,3}. There is a need to identify biomarkers that may identify people at increased risk of stroke.

Inflammatory cytokines are elevated in ischemic stroke⁴. Elevated circulating interleukin-6 (IL-6) is associated with a poorer outcome in patients with acute ischemic stroke (AIS)^{5,6} and predicts recurrent

stroke in patients with small vessel disease⁷. Elevated levels of matrix metalloproteinase (MMP)-9 are associated with infarct growth and hemorrhagic transformation in patients admitted with acute ischemic stroke⁸, whilst lower levels are associated with a better pre-stroke collateral status⁹. Whilst serum vascular endothelial growth factor (VEGF) levels were lower in patients with TIA or AIS¹⁰, elevated VEGF levels were associated with larger infarct volume, post stroke cognitive impairment¹¹ and poorer outcome¹². Although, a recent systematic review and meta-analysis has shown no association between serum VEGF levels and outcomes in ischemic stroke¹³. In an earlier study, elevated E-selectin levels were independently associated with poorer outcomes in patients with ischemic stroke¹⁴. However in a more recent prospective analysis of the EPIC-Heidelberg study, there was no association between E-selectin or P-selectin levels and risk of incident stroke¹⁵.

Corneal confocal microscopy (CCM) is a non-invasive ophthalmic imaging technique that has identified corneal nerve loss in patients with diabetic neuropathy^{16–18}, other peripheral neuropathies¹⁹, multiple sclerosis^{20,21} and dementia²². Recently, we have shown a significant loss of corneal nerves in patients with TIA²³, acute ischemic stroke^{24–27} and recurrent stroke²⁸ indicating that it may be a surrogate marker for the risk of stroke. Increased plasma adhesion molecules including P-selectin and ICAM-1 predict the development of diabetic neuropathy over 5 years²⁹ and elevated IL-6 has been associated with distal neuropathy in subjects with impaired glucose tolerance³⁰.

This study was conducted to investigate whether there is an association between corneal nerve loss and circulating vascular and inflammatory markers in patients with TIA and stroke.

Results

Clinical, Metabolic and Corneal Confocal Microscopy Measures

Clinical, metabolic and CCM parameters in the study participants are given in Table 1.

Table 1
Clinical, metabolic, corneal nerve and circulatory markers in study participants.

Characteristics	Controls	TIA	Stroke
Number of Participants	56	24	81
Age (years)	47.39 ± 18.23	48.75 ± 10.04	50.36 ± 10.30
BMI (kg/m ²)	28.14 ± 4.86	27.42 ± 3.30	27.53 ± 4.11
NIHSS Score	NA	0.54 ± 1.02	3.27 ± 3.40*
Triglycerides (mmol/l)	1.52 ± 1.28	1.75 ± 0.66	1.54 ± 0.84
Total Cholesterol (mmol/l)	4.99 ± 0.84	5.13 ± 1.55	4.80 ± 1.07
LDL (mmol/l)	3.07 ± 0.75	3.01 ± 1.00	3.15 ± 0.97
HDL (mmol/l) ***	1.27 ± 0.34	1.14 ± 0.63‡	0.95 ± 0.25‡
BP Systolic (mmHg)***	128.95 ± 15.12	158.38 ± 24.72‡	159.44 ± 29.39‡
HbA _{1c} (%) ***	5.53 ± 0.42	6.43 ± 1.40‡	6.75 ± 2.14‡
CNFL (mm/mm ²) ***	24.07 ± 4.96	17.87 ± 6.52‡	17.01 ± 5.59‡
CNFD (no./mm ²) ***	34.89 ± 6.69	30.67 ± 10.29	29.14 ± 8.79‡
CNBD (no./mm ²) ***	91.86 ± 44.03	56.89 ± 32.65‡	50.08 ± 31.93‡
IL-6 (pg/ml)	NA	3.12 ± 2.25	5.79 ± 6.63*
MMP-2 (ng/ml)	NA	156.85 ± 48.36	160.57 ± 46.45
MMP-9 (ng/ml)	NA	148.26 ± 78.87	169.46 ± 74.99
E-Selectin (ng/ml)	NA	38.26 ± 17.77	47.47 ± 18.31*
P-Selectin (ng/ml)	NA	49.71 ± 27.33	51.43 ± 2074
VEGF (pg/ml)	NA	43.11 ± 26.09	39.77 ± 21.93
Results are expressed as Mean ± SD. Statistically different results between groups using ANOVA: *** P<= 0.001. ‡ Post hoc results significantly different from controls (P<0.05). * Statistically different results between patients with TIA and stroke (P<0.05).			

Eighty-one patients with acute ischemic stroke and 24 patients with TIA were compared with 56 age-matched healthy controls. Age (P=0.634, P=1.000), BMI (P=1.000, P=1.000), triglycerides (P=1.000, P=1.000), total cholesterol (P=1.000, P=1.000) and LDL (P=1.000, P=1.000) in patients with AIS and TIA were comparable to healthy controls. HDL (P=0.000, P=0.009), CNFL (P=0.000, P=0.000), CNFD (P=0.000, P=0.122) and CNBD (P=0.000, P=0.002) were lower and systolic BP (P=0.000, P=0.000) and HbA_{1c}

(P=0.000, P=0.002) were higher in patients with AIS and TIA compared to controls with no difference between patients with AIS and TIA (Fig. 1).

The NIHSS Score (P = 0.000), IL-6 (P=0.011) and E-Selectin (P=0.032) were higher with no difference in MMP-2 (P=0.636), MMP-9 (P= 0.098), P-Selectin (P=0.395) and VEGF (P=0.831) in patients with AIS compared to TIA.

Correlation Of Ccm Parameters With Inflammatory Markers

IL-6 correlated with CNFD (r=0.230, P=0.019) and CNFL (r=0.218, P=0.026) with no association between corneal nerve parameters and other circulating biomarkers (Table 2).

Table 2
Correlation between corneal nerve parameters and circulating markers.

Participants	IL-6 (pg/ml)	MMP-2 (ng/ml)	MMP-9 (ng/ml)	E-selectin (ng/ml)	P-Selectin (ng/ml)	VEGF pg/ml
CNFD, r	0.230*	-0.049	-0.006	0.031	0.047	0.023
P	0.019	0.623	0.951	0.751	0.631	0.819
CNFL, r	0.218*	-0.069	0.021	0.059	0.121	0.008
P	0.026	0.486	0.831	0.551	0.217	0.936
CNBD, r	0.075	-0.012	-0.049	-0.003	0.099	0.055
P	0.444	0.903	0.622	0.974	0.314	0.574

Multiple Linear Regression

Multiple regression analysis showed a positive association between CNFL (Table 3) and CNFD (Table 4) with IL-6 and a negative association with age. The CNBD distribution was skewed and was not included in the regression analysis.

Table 3
Independent factors for altered CNFL in patients with TIA and stroke.

Dependent Variable: CNFL	B	Std. Error	Beta	95% CI		Significance
				Lower Bound	Upper Bound	
(Constant)	26.885	5.566		15.824	37.947	.000
Age (years)	-.199	.057	-.344	-.313	-.084	.001
Triglycerides (mmol/l)	-1.338	.911	-.168	-3.148	.472	.145
Total Cholesterol (mmol/l)	.727	.933	.149	-1.126	2.581	.438
LDL (mmol/l)	-.491	1.110	-.081	-2.697	1.715	.659
BP Systolic (mmHg)	-.004	.021	-.022	-.046	.037	.830
HbA _{1c} (%)	-.093	.320	-.032	-.730	.544	.772
IL-6 (pg/ml)	.198	.095	.205	.009	.387	.041
MMP-2 (ng/ml)	-.004	.012	-.034	-.029	.020	.728
MMP-9 (ng/ml)	-.002	.008	-.024	-.017	.014	.819
E-selectin (ng/ml)	.006	.036	.019	-.066	.078	.865
P-Selectin (ng/ml)	.026	.030	.095	-.035	.086	.403
VEGF (pg/ml)	.000	.027	-.001	-.053	.052	.990

Table 4
Independent factors for altered CNFD in patients with TIA and stroke.

Dependent Variable: CNFD	B	Std. Error	Beta	95% CI		Significance
				Lower Bound	Upper Bound	
(Constant)	47.556	8.823		30.022	65.091	.000
Age (years)	-.320	.091	-.351	-.500	-.139	.001
Triglycerides (mmol/l)	-2.102	1.444	-.168	-4.971	.767	.149
Total Cholesterol (mmol/l)	.902	1.479	.118	-2.037	3.840	.543
LDL (mmol/l)	-.975	1.760	-.102	-4.472	2.522	.581
BP Systolic (mmHg)	-.001	.033	-.002	-.066	.064	.982
HbA _{1c} (%)	-.218	.508	-.047	-1.227	.791	.669
IL-6 (pg/ml)	.310	.151	.204	.010	.609	.043
MMP-2 (ng/ml)	-.008	.020	-.042	-.047	.031	.672
MMP-9 (ng/ml)	-.003	.013	-.026	-.028	.022	.803
E-selectin (ng/ml)	.016	.057	.031	-.098	.130	.779
P-Selectin (ng/ml)	.003	.048	.007	-.093	.099	.950
VEGF (pg/ml)	.017	.042	.043	-.066	.101	.682

Discussion

In the present study, we show that patients admitted with TIA or acute ischemic stroke have corneal nerve loss. These data support our previous smaller studies showing a loss of corneal nerves in patients with TIA²³ and acute ischemic stroke²⁴. Moreover, we now show that the severity of corneal nerve loss is comparable between patients with TIA and major stroke. Recently, we have also shown greater corneal nerve loss in patients with recurrent stroke, despite comparable vascular risk factors²⁸.

Vascular factors play an integral role in the development and progression of ischemic stroke. Mounting evidence shows that circulating biomarkers are associated with incident stroke⁷ and poorer outcomes after stroke^{5,6,12}. Endothelial extracellular vesicles have prothrombotic properties and we have recently shown an increase in patients with TIA and ischemic stroke³¹. The current study did not find an elevation in E-selectin, P-selectin or VEGF or a relationship with corneal nerve loss in patients with TIA or stroke. Although, previously we have shown that corneal nerve fibre loss is independently associated with the presence of white matter hyperintensities in patients with ischemic stroke²⁶. We have also shown a

reduction in corneal nerves and endothelial cell density in patients with TIA and minor ischemic stroke²³ and an independent association between corneal endothelial cell density, area and perimeter and acute ischemic stroke²⁴.

In the present study, we show that patients with acute TIA and AIS have an increase in IL-6 and MMP-2. The level of IL-6 at admission has been associated with the severity of infarct and neurological outcomes on day 28³². Furthermore, the level of IL-6, fibrinogen and white blood cells had a comparable predictive ability to admission NIHSS and infarct size on recovery from stroke at 6-months³³. However, it is important to note that the time course for appearance of various biomarkers may vary. Thus, monocyte chemotactic protein-1 (MCP-1), matrix metalloproteinase-9 (MMP-9) and interleukin-6 (IL-6) appear within hours of a stroke, but tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), C-reactive protein (CRP), and S100B appear after 12-24 hours and each biomarker had differing abilities to predict 90-day outcomes of stroke³⁴. More recently, IL-6 levels correlated with the severity of stroke at admission based on the NIHSS and mRS and also predicted recurrence of stroke³⁵. The Reasons for Geographic and Racial Differences in Stroke (REGARDS) study enrolled 30,237 participants and showed that IL-6, but not IL-8 or IL-10 was strongly associated with risk of incident stroke over 5.4 years³⁶.

IL-6 has been traditionally considered to be a pro-inflammatory cytokine integral to initiating the acute phase response of the immune system^{37,38}. However, it is increasingly recognized as a multifunctional cytokine capable of eliciting both pro- and anti-inflammatory effects³⁹. Indeed, in the present study, higher levels of IL-6 were independently associated with a higher CNFD and CNFL, despite a loss of corneal nerves in patients with TIA and stroke. In this context, IL-6 has been associated with axonal regeneration following inflammation⁴⁰ and intrathecal delivery of IL-6 leads to activation of pyramidal cells in the sensory motor cortex following spinal cord injury⁴¹. In the context of peripheral nerves, IL-6 receptor is expressed on Schwann cells and following nerve transection the administration of IL-6/IL-6R fusion protein resulted in a four-fold increase in myelinated nerve fiber regrowth⁴². IL-6 is also intimately involved in axonal regeneration as it induces increased expression of growth associated protein-43 (GAP-43)⁴³. IL-6 deficient mice display reduced amplitude of sensory action potentials and temperature sensitivity and impaired axonal regeneration following sciatic nerve crush injury⁴⁴.

This study has limitations. CCM was not performed in patients with severe disability due to their inability to cooperate during the CCM procedure. This may have biased the outcomes as the results may have been even more pronounced in those with more severe stroke. Second, circulatory markers and neurological outcomes were only measured at one time point.

In conclusion, we show greater corneal nerve loss in patients with stroke and TIA compared to healthy controls and contrary to our initial hypothesis we show that elevated IL-6 levels were independently associated with greater corneal nerve measures. To assess the utility of CCM in ischemic stroke, larger, longitudinal studies assessing corneal nerve fibre morphology and their association with circulating markers of inflammation and vascular integrity are required.

Materials And Methods

One hundred and five patients-admitted with transient ischemic attack (n=24) and acute ischemic stroke (n=81) were recruited from the stroke ward at Hamad General Hospital. The diagnosis of TIA and stroke were confirmed clinically and radiologically using AHA criteria ⁴⁵. Exclusion criteria included patients with a known history of ocular trauma or surgery, glaucoma, dry eye and corneal dystrophy ⁴⁶. Demographic (age, gender, ethnicity) and clinical (blood pressure, HbA_{1c}, lipid profile) data were obtained from the admission patients' electronic health records. All patients underwent assessment of the National Institutes of Health Stroke Scale (NIHSS) at presentation. This study adhered to the tenets of the declaration of Helsinki and was approved by the Institutional Review Board of Weill Cornell Medicine (15-00021) and Hamad General Hospital (15304/15). Informed, written consent was obtained from all patients/guardians before participation in the study.

Corneal Confocal Microscopy

All patients underwent CCM (Heidelberg Retinal Tomograph III Rostock Cornea Module; Heidelberg Engineering GmbH, Heidelberg, Germany). CCM uses a 670 nm wavelength helium neon diode laser, which is a class I laser and therefore does not pose any ocular safety hazard. A ×63 objective lens with a numeric aperture of 0.9 and a working distance, relative to the applanating cap (TomoCap; Heidelberg Engineering GmbH) of 0.0 to 3.0 mm, is used. The size of each 2-dimensional image produced is 384×384 pixels with a 15°×15° field of view and 10 μm/pixel transverse optical resolutions. To perform the CCM examination, local anesthetic (0.4% benoxinate hydrochloride; Chauvin Pharmaceuticals, Chefaro, United Kingdom) was used to anesthetize both eyes, and Viscotears (Carbomer 980, 0.2%, Novartis, United Kingdom) was used as the coupling agent between the cornea and the cap. Patients were asked to fixate on an outer fixation light throughout the CCM scan and a CCD camera was used to correctly position the cap onto the cornea ⁴⁷. The examination took approximately 10 minutes for both eyes. The examiners captured images of the central sub-basal nerve plexus using the section mode. On the basis of depth, contrast, focus, and position, 6 images per patient were selected ⁴⁸. All CCM images were manually analyzed using validated, purpose-written software. Corneal nerve fiber density (CNFD), corneal nerve branch density (CNBD) and corneal nerve fiber length (CNFL) were analyzed using CCMetrics (M. A. Dabbah, ISBE, University of Manchester, Manchester, United Kingdom) ¹⁶.

Blood Collection

Following consent, within 48 hours of admission, peripheral venous blood (5mL) from patients was collected in ethylenediaminetetraacetic acid (EDTA) tubes (Vacutainers; Becton Dickinson) by using a 21-gauge needle to reduce platelet stimulation. The tubes containing the blood were immediately transferred on ice to the stroke research laboratory and centrifuged within 60 minutes at 1,500 g for 15 minutes at 4°C to obtain platelet poor plasma. The Plasma was immediately snap frozen and stored at -80°C until

biomarker quantification. MMP-9, MMP-2, IL-6, E-Selectin, P-Selectin and VEGF-A levels in the plasma were measured by enzyme-linked immunosorbent assay (ELISA) using MMP-9 Human ELISA Kit (Cat: DMP900), MMP-2 Human ELISA Kit (Cat: MMP200), IL-6 Human ELISA Kit (Cat: D6050), E-Selectin Human ELISA Kit (Cat: DSLE00), P-Selectin Human ELISA Kit (Cat: DPSE00) and VEGF Human ELISA Kit (Cat: DVE00). All the ELISA kits were procured from R&D Systems, Inc. Minneapolis MN, USA. The ELISA was performed according to the manufacturer's instructions.

Statistical Analysis

All statistical analyses were performed using IBM SPSS Statistics software Version 25. Normality of the data was assessed using the Shapiro-Wilk test and by visual inspection of the histogram and a normal Q-Q plot. Data are expressed as mean $\pm$ standard deviation (SD). Mann Whitney test (for non-normally distributed variables) and t-test (for normally distributed variables) were performed to find the differences between two groups, and one-way ANOVA was performed to find the differences between three groups and Bonferroni correction was performed. Pearson correlation was performed to find association between corneal nerves and circulatory biomarkers. Multiple linear regression analysis was conducted to evaluate the independent association between CNFL and CNFD and covariates.

Declarations

Funding

Supported by Qatar National Research Fund Grant BMRP20038654 to Professor Rayaz A. Malik. Medical Research Council Grant HMC # 15304/15 to Dr. Naveed Akhtar. The funders had no role in study design, data collection and analysis, decision to publish, or publish, or preparation of the manuscript.

Conflict of Interest/Competing Interests

The authors declare that they have no conflict of interest.

Ethics Approval

This study adhered to the tenets of the declaration of Helsinki and was approved by the Institutional Review Board of Weill Cornell Medicine (15-00021) and Hamad General Hospital (15304/15).

Consent to participate

Informed, written consent was obtained from all patients/guardians before participation in the study.

Consent for publication

Written consent was obtained from all patients/guardians for publications.

Availability of data and material

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author' contributions

Conceptualization: AK and RAM; Methodology: AK and AP; Software: AK; Validation: AK, AP, RAM, AS; Formal Analysis: AK and AP; Investigation: AK, AP, NA, AA, SK, SVP, RP, HG, GP, INP, KC, KT; MS; Resources: AS, NA and RAM; Data Curation: AK and AP; Writing – Original Draft Preparation: AK; Writing Review & Editing: AK, AS and RAM; Visualization: AK and RAM; Supervision: AS and RAM; Project Administration: AS, RAM and NA; Funding Acquisition: AS, RAM and NA.

References

1. Tong, X. *et al.* The burden of cerebrovascular disease in the united states. *Prev. Chronic Dis*, **16**, E52 (2019).
2. Kissela, B. M. *et al.* Age at stroke: temporal trends in stroke incidence in a large, biracial population. *Neurology*, **79**, 1781–1787 (2012).
3. Akhtar, N. *et al.* Prolonged stay of stroke patients in the emergency department may lead to an increased risk of complications, poor recovery, and increased mortality. *Journal of Stroke and Cerebrovascular Diseases*, **25**, 672–678 (2016).
4. Zhu, X. *et al.* RNA DLGAP4 is down-regulated and negatively correlates with severity, inflammatory cytokine expression and pro-inflammatory gene miR-143 expression in acute ischemic stroke patients. *International Journal of Clinical and Experimental Pathology*, **12**, 941 (2019).
5. Klimiec-Moskal, E. *et al.* The specific ex vivo released cytokine profile is associated with ischemic stroke outcome and improves its prediction. *Journal of Neuroinflammation*, **17**, 7 (2020).
6. Feng, L., Guo, J. & Ai, F. Circulating long noncoding RNA ANRIL downregulation correlates with increased risk, higher disease severity and elevated pro-inflammatory cytokines in patients with acute ischemic stroke. *Journal of Clinical Laboratory Analysis*, **33**, e22629 (2019).
7. Staszewski, J., Skrobowska, E., Piusińska-Macoch, R., Brodacki, B. & Stępień, A. IL-1 α and IL-6 predict vascular events or death in patients with cerebral small vessel disease—Data from the SHEF-CSVD study. *Advances in Medical Sciences*, **64**, 258–266 (2019).
8. Mechtouff, L. *et al.* Matrix Metalloproteinase-9 relationship with infarct growth and hemorrhagic transformation in the era of thrombectomy. *Frontiers in Neurology*, **11**, 473 (2020).
9. Mechtouff, L. *et al.* Matrix Metalloproteinase-9 and Monocyte Chemoattractant Protein-1 are associated with collateral status in acute ischemic stroke with large vessel occlusion., **51**, 2232–2235 (2020).
10. Giordano, M. *et al.* Circulating miRNA-195-5p and-451a in diabetic patients with transient and acute ischemic stroke in the emergency department. *International Journal of Molecular Sciences*, **21**, 7615 (2020).

11. Prodjohardjono, A., Vidyanti, A. N., Susianti, N. A., Sutarni, S. & Setyopranoto, I. Higher level of acute serum VEGF and larger infarct volume are more frequently associated with post-stroke cognitive impairment. *PloS One*, **15**, e0239370 (2020).
12. Zhang, Y., Ma, T., Hu, H., Wang, J. & Zhou, S. Serum vascular endothelial growth factor as a biomarker for prognosis of minor ischemic stroke. *Clinical Neurology and Neurosurgery*, **196**, 106060 (2020).
13. Seidkhani-Nahal, A. *et al.* Serum vascular endothelial growth factor (VEGF) levels in ischemic stroke patients: a systematic review and meta-analysis of case–control studies. *Neurological Sciences*, **1–10**(2020).
14. Richard, S. *et al.* E-selectin and vascular cell adhesion molecule-1 as biomarkers of 3-month outcome in cerebrovascular diseases. *Journal of Inflammation*, **12**, 61 (2015).
15. Pletsch-Borba, L. *et al.* Vascular injury biomarkers and stroke risk: A population-based study. *Neurology*, **94**, e2337–e2345 (2020).
16. Petropoulos, I. N. *et al.* Rapid automated diagnosis of diabetic peripheral neuropathy with in vivo corneal confocal microscopy. *Invest Ophthalmol Vis Sci*, **55**, 2071–2078 <https://doi.org/10.1167/iovs.13-13787> (2014).
17. Fadavi, H. *et al.* Explanations for less small fibre neuropathy in South Asian versus European people with type 2 diabetes mellitus in the UK. *Diabetes Metab Res Rev*, **34**, e3044 <https://doi.org/10.1002/dmrr.3044> (2018).
18. Chen, X. *et al.* Corneal nerve fractal dimension: A novel corneal nerve metric for the diagnosis of diabetic sensorimotor polyneuropathy. *Invest Ophthalmol Vis Sci*, **59**, 1113–1118 <https://doi.org/10.1167/iovs.17-23342> (2018).
19. Khan, A. *et al.* Corneal confocal microscopy detects severe small fiber neuropathy in diabetic patients with Charcot neuroarthropathy. *J Diabetes Investig*, **9**, 1167–1172 (2018).
20. Mikolajczak, J. *et al.* Patients with multiple sclerosis demonstrate reduced subbasal corneal nerve fibre density. *Mult Scler*, **23**, 1847–1853 <https://doi.org/10.1177/1352458516677590> (2017).
21. Khan, A. *et al.* Corneal langerhans cells are Increased in patients with multiple sclerosis. (2021).
22. Ponirakis, G. *et al.* Association of corneal nerve fiber measures with cognitive function in dementia. *Ann Clin Transl Neurol*, **6**, 689–697 (2019).
23. Gad, H. *et al.* Corneal nerve and endothelial cell damage in patients with transient ischemic attack and minor ischemic stroke. *PloS One* **14**, e0213319, doi:0.1371/journal.pone.0213319(2019).
24. Khan, A. *et al.* Corneal confocal microscopy detects corneal nerve damage in patients admitted with acute ischemic stroke., **48**, 3012–3018 <https://doi.org/10.1161/STROKEAHA.117.018289> (2017).
25. Khan, A. *et al.* Corneal confocal microscopy detects a reduction in corneal endothelial cells and nerve fibres in patients with acute ischemic stroke. *Sci Rep*, **8**, 17333 (2018).
26. Kamran, S. *et al.* Cornea: A window to white matter changes in stroke; corneal confocal microscopy a surrogate marker for the presence and severity of white matter hyperintensities in ischemic stroke. *J*

27. Khan, A. *et al.* Corneal nerve loss as a surrogate marker for poor pial collaterals in patients with acute ischemic stroke. *Scientific reports*, **11**, 19718–19718 <https://doi.org/10.1038/s41598-021-99131-0> (2021).
28. Khan, A. *et al.* Corneal confocal microscopy identifies greater corneal nerve damage in patients with a recurrent compared to first ischemic stroke. *PloS One*, **15**, e0231987 (2020).
29. Jude, E. *et al.* The potential role of cell adhesion molecules in the pathogenesis of diabetic neuropathy., **41**, 330–336 (1998).
30. Tiftikcioglu, B. I., Duksal, T., Bilgin, S., Kose, S. & Zorlu, Y. Association between the levels of IL-6, sE-selectin and distal sensory nerve conduction studies in patients with prediabetes. *Eur. Neurol*, **75**, 124–131 (2016).
31. Agouni, A. *et al.* There is selective increase in pro-thrombotic circulating extracellular vesicles in acute ischemic stroke and transient ischemic attack: A study of patients from the Middle East and Southeast Asia. *Frontiers in neurology*, **10**, 251 (2019).
32. Nakase, T., Yamazaki, T., Ogura, N., Suzuki, A. & Nagata, K. The impact of inflammation on the pathogenesis and prognosis of ischemic stroke. *Journal of the Neurological Sciences*, **271**, 104–109 (2008).
33. Clark, W. M., Beamer, N. B., Wynn, M. & Coull, B. M. The initial acute phase response predicts long-term stroke recovery. *Journal of Stroke and Cerebrovascular Diseases*, **7**, 128–131 (1998).
34. Worthmann, H. *et al.* The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome. *Cerebrovasc. Dis*, **30**, 85–92 (2010).
35. Aref, H. M. A. *et al.* Role of interleukin-6 in ischemic stroke outcome. *The Egyptian Journal of Neurology, Psychiatry and Neurosurgery*, **56**, 1–7 (2020).
36. Jenny, N. S. *et al.* Inflammatory cytokines and ischemic stroke risk: The REGARDS cohort. *Neurology*, **92**, e2375–e2384 (2019).
37. Yasukawa, K. *et al.* Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. *The EMBO journal*, **6**, 2939–2945 (1987).
38. Hirano, T. *et al.* Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). *Proceedings of the National Academy of Sciences* **82**, 5490-5494(1985).
39. Rothaug, M., Becker-Pauly, C. & Rose-John, S. The role of interleukin-6 signaling in nervous tissue. *Biochimica et Biophysica Acta (BBA)-Molecular Cell Research*, **1863**, 1218–1227 (2016).
40. Leibinger, M. *et al.* Interleukin-6 contributes to CNS axon regeneration upon inflammatory stimulation. *Cell death & Disease*, **4**, e609–e609 (2013).
41. Yang, P., Qin, Y., Bian, C., Zhao, Y. & Zhang, W. Intrathecal delivery of IL-6 reactivates the intrinsic growth capacity of pyramidal cells in the sensorimotor cortex after spinal cord injury. *PLoS One*, **10**, e0127772 (2015).

42. Haggiag, S. *et al.* Stimulation of myelin gene expression in vitro and of sciatic nerve remyelination by interleukin-6 receptor–interleukin-6 chimera. *Journal of Neuroscience Research*, **64**, 564–574 (2001).
43. Cafferty, W. B. *et al.* Conditioning injury-induced spinal axon regeneration fails in interleukin-6 knock-out mice. *Journal of Neuroscience*, **24**, 4432–4443 (2004).
44. Zhong, J., Dietzel, I. D., Wahle, P., Kopf, M. & Heumann, R. Sensory impairments and delayed regeneration of sensory axons in interleukin-6-deficient mice. *J Neurosci*, **19**, 4305–4313 (1999).
45. Powers, W. J. *et al.* 2018 Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* **49**, e46–e110, doi:10.1161/STROKEAHA.119.026917 (2018).
46. Shukla, A. N., Cruzat, A. & Hamrah, P. Confocal microscopy of corneal dystrophies. *Seminars in Ophthalmology*, **27**, 107–116 <https://doi.org/10.3109/08820538.2012.707276> (2012).
47. Tavakoli, M. & Malik, R. A. Corneal confocal microscopy: a novel non-invasive technique to quantify small fibre pathology in peripheral neuropathies. *J Vis Exp*, 1–7 <https://doi.org/10.3791/2194> (2011).
48. Vagenas, D. *et al.* Optimal image sample size for corneal nerve morphometry. *Optom Vis Sci*, **89**, 812–817 <https://doi.org/10.1097/OPX.0b013e31824ee8c9> (2012).

Figures

Figure 1

CCM image of the sub-basal nerve plexus in a control participant (A) and a patient with TIA (B) and an acute ischemic stroke (C).